Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
The Dongguk University Industry-Academic Cooperation Foundation has 5 pending office actions distributed across the Biotechnology & Pharmaceuticals technology area. These matters are spread among 5 distinct examiners and a quintet of distinct art units, showing a lack of examiner or art unit concentration in the current portfolio.
SOOD, ANSHUL is identified as the busiest examiner, though they are responsible for only 1 pending office action. The one-to-one ratio of pending actions to examiners and art units suggests that each filing is being evaluated independently by different personnel across various specialized groups within the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOOD, ANSHUL | 1 | 83.1% | +12.5% |
| MCKOY, QUINCY ANDRE | 1 | 68.4% | +39.8% |
| WERTZ, ASHLEE ELIZABETH | 1 | 52.7% | +35.6% |
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
| GIBBS, TERRA C | 1 | 63.7% | +10.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19178815 | DEVICE AND METHOD FOR SAMPLING-BASED PATH PLANNING USING MIDPOINT INTERPOLATION METHOD | SOOD, ANSHUL | — |
| 18289798 | FOLIC ACID-CONJUGATED AMINOCLAY BASED NANOCOMPOSITES FOR THE SITE-SPECIFIC DRUG DELIVERY, METHOD FOR THEIR PREPARATION AND THEIR USE | WERTZ, ASHLEE ELIZABETH | — |
| 18707936 | COMPOSITION FOR CURING HANGOVER OR IMPROVING LIVER FUNCTION, COMPRISING PINE HEARTWOOD EXTRACT AS ACTIVE INGREDIENT | FIEBIG, RUSSELL G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | GIBBS, TERRA C | 20d |
| 19178815 | DEVICE AND METHOD FOR SAMPLING-BASED PATH PLANNING USING MIDPOINT INTERPOLATION METHOD | SOOD, ANSHUL | — |
| 18723672 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | MCKOY, QUINCY ANDRE | — |
| 18289798 | FOLIC ACID-CONJUGATED AMINOCLAY BASED NANOCOMPOSITES FOR THE SITE-SPECIFIC DRUG DELIVERY, METHOD FOR THEIR PREPARATION AND THEIR USE | WERTZ, ASHLEE ELIZABETH | — |
| 18707936 | COMPOSITION FOR CURING HANGOVER OR IMPROVING LIVER FUNCTION, COMPRISING PINE HEARTWOOD EXTRACT AS ACTIVE INGREDIENT | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 3667 | 1 |
| 1626 | 1 |
| 1612 | 1 |
| 1655 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19178815 | DEVICE AND METHOD FOR SAMPLING-BASED PATH PLANNING USING MIDPOINT INTERPOLATION METHOD | SOOD, ANSHUL | 3667 | §101§102§112 | Non-Final OA | — | Pending | Apr 14, 2025 |
| 18723672 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | MCKOY, QUINCY ANDRE | 1626 | §102DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18289798 | FOLIC ACID-CONJUGATED AMINOCLAY BASED NANOCOMPOSITES FOR THE SITE-SPECIFIC DRUG DELIVERY, METHOD FOR THEIR PREPARATION AND THEIR USE | WERTZ, ASHLEE ELIZABETH | 1612 | §103§112 | Final Rejection | — | Pending | Jun 10, 2024 |
| 18707936 | COMPOSITION FOR CURING HANGOVER OR IMPROVING LIVER FUNCTION, COMPRISING PINE HEARTWOOD EXTRACT AS ACTIVE INGREDIENT | FIEBIG, RUSSELL G | 1655 | §101§103§112 | Final Rejection | — | Pending | May 07, 2024 |
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | GIBBS, TERRA C | 1635 | §112 | Final Rejection | 20d | Pending | Jul 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDongguk University Industry-Academic Cooperation Foundation has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Anshul Sood has the most, with 1 of Dongguk University Industry-Academic Cooperation Foundation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
